Complete Up To Date Information about Betasone Aqueous Suspension.
NADA Number: 049-185 | |
| Proprietary Name |
Betasone Aqueous Suspension |
|---|---|
| Sponsor |
Schering-Plough Animal Health Corp. |
| Sponsor Address |
P.O. Box 21 Sandown Village, NJ 3171 VIC Australia |
| Ingredients |
Betamethasone Dipropionate Betamethasone Sodium Phosphate |
| Species |
Horse, not for meat production Dog, restricted during pregnancy Horse, restricted during pregnancy |
| Routes of Administration |
Intramuscular (canine) Intra-articular (equine) |
| Dose Form |
Liquid (suspension) |
| Drug Form |
Liquid (suspension) |
| Dispensing Status |
RX |
| Patent Number |
3733408 |
|
Dosage Amount, Indications & Limitations |
522.163 Betamethasone dipropionate and betamethasone sodium phosphate aqueous suspension. Specifications: Betamethasone dipropionate and betamethasone sodium phosphate aqueous suspension is a sterile aqueous suspension. Each milliliter of the suspension contains the equivalent of 5 milligrams of betamethasone as betamethasone dipropionate and 2 milligrams of betamethasone as betamethasone sodium phosphate. Conditions of use: Dogs Amount: It is administered by intramuscular injection at a dosage of 0.25 to 0.5 milliliter per 20 pounds of body weight, depending on the severity of the condition. Frequency of dosage depends on recurrence of pruritic symptoms. Dosage may be repeated every 3 weeks or when symptoms recur, not to exceed a total of 4 injections. Indications: It is used as an aid in the control of pruritus associated with dermatoses. Limitations: It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Horses Amount: It is administered aseptically by intraarticular injection at a dosage of 2.5 to 5 milliliters per joint, depending on the severity of the condition and the joint size. Dosage may be repeated upon recurrence of clinical signs. Injection into the joint cavity should be preceded by withdrawal of synovial fluid. Indications: It is used as an aid in the control of inflammation associated with various arthropathies. Limitations: Not for use in horses intended for food. It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. |